Radius Health Inc. (RDUS) Trading Up 4.1%
Radius Health Inc. (NASDAQ:RDUS)’s share price traded up 4.1% on Friday . The company traded as high as $41.07 and last traded at $40.58, with a volume of 228,030 shares. The stock had previously closed at $39.00.
Several equities research analysts have recently commented on RDUS shares. Zacks Investment Research raised Radius Health from a “sell” rating to a “hold” rating in a report on Tuesday, July 5th. Canaccord Genuity reissued a “buy” rating on shares of Radius Health in a report on Tuesday, May 31st. HC Wainwright started coverage on Radius Health in a report on Monday, May 23rd. They issued a “buy” rating and a $55.00 price objective for the company. Cowen and Company started coverage on Radius Health in a report on Friday, May 6th. They issued an “outperform” rating for the company. Finally, Cantor Fitzgerald reissued a “buy” rating and issued a $70.00 price objective on shares of Radius Health in a report on Thursday, March 31st. Three equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average price target of $70.07.
The firm has a 50-day moving average of $37.41 and a 200-day moving average of $36.07. The stock’s market cap is $1.74 billion.
Radius Health (NASDAQ:RDUS) last released its quarterly earnings data on Thursday, May 5th. The biopharmaceutical company reported ($0.94) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.74) by $0.20. The company’s quarterly revenue was up .0% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.47) earnings per share. On average, equities analysts forecast that Radius Health Inc. will post ($3.71) earnings per share for the current fiscal year.
Other large investors have recently added to or reduced their stakes in the company. Dimensional Fund Advisors LP purchased a new stake in Radius Health during the fourth quarter valued at approximately $1,362,000. Wells Fargo & Company MN increased its stake in Radius Health by 7.5% in the fourth quarter. Wells Fargo & Company MN now owns 422,217 shares of the biopharmaceutical company’s stock valued at $25,984,000 after buying an additional 29,601 shares in the last quarter. Mutual of America Capital Management LLC increased its stake in Radius Health by 18.5% in the fourth quarter. Mutual of America Capital Management LLC now owns 36,483 shares of the biopharmaceutical company’s stock valued at $2,245,000 after buying an additional 5,683 shares in the last quarter. EAM Investors LLC purchased a new stake in Radius Health during the fourth quarter valued at approximately $2,816,000. Finally, New York State Common Retirement Fund increased its stake in Radius Health by 36.0% in the fourth quarter. New York State Common Retirement Fund now owns 69,048 shares of the biopharmaceutical company’s stock valued at $4,249,000 after buying an additional 18,259 shares in the last quarter.
Radius Health, Inc is a science-driven biopharmaceutical company focused on developing therapeutics for patients with osteoporosis, oncology and endocrine diseases. The Company’s lead product candidate is the investigational drug abaloparatide for subcutaneous injection (abaloparatide-SC), which has completed Phase III development for potential use in the reduction of fracture risk in postmenopausal women with osteoporosis.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.